GENFIT moves focus to promising NASH diagnosticLaurent DECORYDec 12, 20201 min readIn a promising but risky NASH market, study shows GENFIT NIS4 easy test allows to identify patients who require treatment, without need for painful liver biopsy. Well done to Pascal Prigent & team. #launch #commercialexcellenceContinue reading
In a promising but risky NASH market, study shows GENFIT NIS4 easy test allows to identify patients who require treatment, without need for painful liver biopsy. Well done to Pascal Prigent & team. #launch #commercialexcellenceContinue reading
Comentarios